DOVATO Dosing

Daily dosing with packaging options to fit your patients’ preferences. With a 30-day supply available in blister or bottle packaging, choose what works best for them.

A Complete Single-Tablet Regimen Designed With Your Patients in Mind

A 30-Day Supply of DOVATO Is Available as an On-the-Go Blister Pack or in a Bottle

Key Features of the DOVATO On-the-Go Blister Pack

Potential Drug Interactions With DOVATO

Established and Other Potentially Significant Drug-to-Drug Interactions

Avoid
Contraindicated
Dofetilide

Avoid Coadministration
Agent Recommendations

Oxcarbazepine

Phenobarbital

Phenytoin

St. John’s wort (Hypericum perforatum)

 Avoid coadministration with DOVATO because there are insufficient data to make dosing recommendations
Sorbitol When possible, avoid use of sorbitol-containing medicines with DOVATO

Because DOVATO is a complete regimen, coadministration with other ARVs for the treatment of HIV-1 infection is not recommended.

Dosing Adjustments and Considerations
Agent Recommendations
Carbamazepine or rifampin An additional dolutegravir 50-mg dose should be taken, separated by 12 hours from DOVATO
Metformin Refer to the Prescribing Information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin
Medications containing polyvalent cations (eg, Mg or Al): cation-containing antacids or laxatives, sucralfate, or buffered medications Administer DOVATO 2 hours before or 6 hours after taking medications containing polyvalent cations
Oral calcium and iron supplements, including multivitamins containing calcium or iron When taken with food, DOVATO and supplements or multivitamins containing calcium or iron can be taken at the same time. Under fasting conditions, DOVATO should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron
Dalfampridine Elevated levels of dalfampridine increase the risk of seizures. The potential benefits of taking dalfampridine concurrently with DOVATO should be considered against the risk of seizures in these patients

Please see Section 7 of the full Prescribing Information for additional drug interaction information.

No Expected Dosing Adjustments1-7

Dolutegravir and Lamivudine, Components of DOVATO, Have No Clinically Relevant Effects on the Pharmacokinetics of the Following Agents

Based on available pharmacokinetics drug interaction studies
Prednisone Oral contraceptive containing norgestimate* and ethinyl estradiol
Midazolam Proton pump inhibitors (omeprazole)
Rifabutin  

Based on pharmacokinetics, metabolic pathways, and/or available drug interaction studies
Hepatitis C drugs, including:
Sofosbuvir Sofosbuvir/velpatasvir
Ledipasvir/sofosbuvir Sofosbuvir/elpatasvir/voxilaprevir
Elbasvir/grazoprevir Glecaprevir/pibrentasvir
Ombitasvir/paritaprevir/ritonavir plus dasabuvir  

*Norelgestromin is the active metabolite of norgestimate, and no drug interaction is expected with norgestimate.8

ABC=abacavir; Al=aluminum; ARV=antiretroviral; Mg=magnesium; NDC=National Drug Code; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

References:

  1. AIDSinfo: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. US Department of Health and Human Services. Accessed September 12, 2024. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
  2. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated December 19, 2023. Accessed March 2, 2022. https://www.hcvguidelines.org/unique-populations/hiv-hcv
  3. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2020.
  4. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2022.
  5. Viekira Pak [package insert]. North Chicago, IL: AbbVie, Inc.; 2019.
  6. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2019.
  7. Mavyret [package insert]. North Chicago, IL: AbbVie, Inc.; 2021.
  8. Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother. 2015;49(7):784-789.

PMUS-DLLWCNT240054 January 2025